Global Leukemia Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Type of Leukemia (Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, and Others), By Treatment (Chemotherapy, Immunotherapy, Targeted Therapy, Car-T Cell Therapy, and Others), By Route of Administration (Oral and Injectable), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Leukemia Therapeutics Market Insights Forecasts to 2035

• The Global Leukemia Therapeutics Market Size Was Estimated at USD 21.95 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 8.05% from 2025 to 2035
• The Worldwide Leukemia Therapeutics Market Size is Expected to Reach USD 51.45 Billion by 2035
• Asia Pacific is Expected to Grow the fastest during the forecast period.

According to a research report published by Spherical Insights and Consulting, The Global Leukemia Therapeutics Market Size was worth around USD 21.95 Billion in 2024 and is Predicted to Grow to around USD 51.45 Billion by 2035 with a Compound Annual Growth Rate (CAGR) of 8.05% from 2025 and 2035. The Market Size for Leukemia Therapeutics has opportunities to Grow owing to the ongoing progress in targeted therapies and immunotherapies in leukemia treatment.   

Market Overview

The Global Industry of Leukemia Therapeutics focuses on the development, production, and sale of treatments for leukemia, which is a type of cancer affecting the blood and bone marrow. Leukemia refers to blood cancers that usually begin in the bone marrow and are characterised by an increased number of abnormal blood cells, called blasts or leukemia cells. Treatment includes a combination of chemotherapy, radiation therapy, targeted therapy, and bone marrow transplant, with supportive and palliative care provided as needed. Leukemia is estimated to be approximately 2.5% of cancer prevalence, and 3.1% of cancer-related deaths, attributed to a number of factors including smoking, radiation exposure, rare congenital diseases, and others. There is ongoing development of novel therapeutic strategies and targeted drugs, making remarkable improvements and a need for developing preventive strategies.

Innovation and market expansion are anticipated as a result of major players' growing research activities for developing different treatment approaches. Immune based therapies like CAR T cells, are being developed for types of leukemia, AML and B-ALL. Further, bone marrow transplant and stem cell therapy are evolving trends in the market. The quick development of artificial intelligence technology for effective diagnostic and therapeutic of leukemia is driving a huge surge in the global leukemia therapeutics market. For instance, in April 2025, Biostate AI, which is a startup building AI for predicting disease evolution and drug response based on RNA sequencing data, and Weill Cornell Medicine entered into a strategic collaboration for developing AI for personalized assessments of patient disease prognosis and evolution.   

Report Coverage

This research report categorizes the leukemia therapeutics market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the leukemia therapeutics market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the leukemia therapeutics market. 

Driving Factors

The leukemia therapeutics market is primarily driven by the growing prevalence and mortality rate of leukemia. For instance, the number of new cases of leukemia found was 66,890, while 23,540 estimated number of deaths in the year 2025. An increasing advancement in leukemia therapeutic regime, including targeted therapies and immunotherapies, along with increased funding, is promoting the market growth. For instance, in June 2025, phase 1 clinical trial studying JBZ-001, for treating AML is supported by a more than $3.4 million grant from National Institutes of Health’s National Cancer Institute awarded to UC and OSUCCC – James.

Restraining Factors

The leukemia therapeutics market is restricted by several acute and chronic side effects caused by leukemia therapies. Further, the limited healthcare spending and patient inaccessibility to expensive and advanced therapies are hindering the market growth. Several macroeconomic and geopolitical factors also affecting the leukemia therapeutics market.

Market Segmentation

The leukemia therapeutics market share is classified into type of leukemia, treatment, and route of administration.   

• The chronic lymphocytic leukemia segment dominated the market with a share of 31.7% in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the type of leukemia, the leukemia therapeutics market is divided into chronic myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, acute myeloid leukemia, and others. Among these, the chronic lymphocytic leukemia segment dominated the market with a share of 31.7% in 2024 and is projected to grow at a substantial CAGR during the forecast period. Chronic lymphocytic leukemia, is one-quarter of new cases of leukemia and accounts for 4.7 per 100,000 men and women per year, as per NCI estimates. Further, an increasing innovations in targeted therapies, along with the expanded research in immunotherapy solutions, and increasing drug approvals are driving the market.

• The targeted therapy segment accounted for the largest revenue share of 40.2% in 2024, and is anticipated to grow at a significant CAGR during the forecast period.

Based on the treatment, the leukemia therapeutics market is divided into chemotherapy, immunotherapy, targeted therapy, CAR-T cell therapy, and others. Among these, the targeted therapy segment accounted for the largest revenue share of 40.2% in 2024, and is anticipated to grow at a significant CAGR during the forecast period. The segment includes novel tyrosine kinase inhibitors and monoclonal antibodies, focusing on cell changes that are responsible for the cause of cancer. The growing advancements in precision medicine and favorable regulatory policies for novel therapy approvals are supporting the market.

• The injectable segment held the largest revenue share of 66.9% in 2024, and is anticipated to grow at a significant CAGR during the forecast period.

Based on the route of administration, the leukemia therapeutics market is divided into oral and injectable. Among these, the injectable segment held the largest revenue share of 66.9% in 2024, and is anticipated to grow at a significant CAGR during the forecast period. The injectable route of administration is most preferable due to its ease of absorption and quick outcomes. Injectable therapies include traditional chemotherapy agents, targeted therapies, immunotherapies, and enzyme-based asparaginase treatments.

Regional Segment Analysis of the Leukemia Therapeutics Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the leukemia therapeutics market over the predicted timeframe.

North America is anticipated to hold the largest share of about 45.5% in the leukemia therapeutics market over the predicted timeframe. The market ecosystem in North America is strong, with increasing partnership with AI health startups for enhancing cancer diagnosis and improving patient care. The market demand for leukemia therapeutics has been driven by the region's developed healthcare infrastructure and emphasis on developing advanced therapeutics. The United States accounts for the major share of the North America leukemia therapeutics market, due to significant investment in the development of advanced therapies such as CAR-T cell therapies.

Asia Pacific is expected to grow at a rapid CAGR of 11.2% in the leukemia therapeutics market during the forecast period. The Asia Pacific area has a thriving market for leukemia therapeutics due to an increasing collaborative approach for advancing disease prevention, research, and patient care. China and India are fastest-growing countries in the leukemia therapeutics market in the Asia Pacific region. Additionally, the growing prevalence of leukemia, increased technological developments, and R&D initiatives for developing advanced therapeutics are promoting market growth.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the leukemia therapeutics market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Amgen Inc.
• Novartis 
• Sanofi/ Genzyme Corporation
• F. Hoffmann-La Roche
• Bristol-Myers Squibb
• Pfizer Inc.
• Lupin Ltd.
• AbbVie
• Johnson & Johnson Services, Inc.
• Takeda Pharmaceutical Co. Ltd. 
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Recent Development

• In October 2025, CytoMed Therapeutics Limited, a Singapore-based clinical stage biopharmaceutical company, develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, announced the publication of a preclinical study, in a research article entitled "Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising "off-the-shelf” Immunotherapy Approach”.

• In September 2025, Made Scientific and Hemogenyx Pharmaceuticals plc announced a manufacturing partnership to advance HG-CT-1, Hemogenyx's Chimeric Antigen Receptor T-cell (CAR-T) therapy and lead clinical program for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML) in adults.

• In August 2025, Intas Pharmaceuticals, in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as one of the world's leading suppliers of pegfilgrastim following the successful acquisition of UDENYCA (pegfilgrastim-cbqv) from Coherus BioSciences, Inc.

• In June 2025, the University of Cincinnati Cancer Center (UC), The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) and Jabez Biosciences are partnering to open a new phase 1 clinical trial studying JBZ-001, a potential new treatment for acute myeloid leukemia (AML).

• In June 2025, Johnson & Johnson announced new Phase 1b data showing antileukemic activity and a promising safety profile for bleximenib (JNJ-75276617) in combination with venetoclax and azacitidine (VEN + AZA) for the treatment of acute myeloid leukemia (AML) harbouring KMT2A gene rearrangements (KMT2Ar) or NPM1 gene mutations (NPM1m).

• In March 2025, Cellogen therapeutics, a Delhi-based biotech straup, has received regulatory approval for the patent of reportedly, the world’s first indigenously developed Bi-Specific 3rd Generation Chimeric Antigen Receptor T (CAR T) cells.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the leukemia therapeutics market based on the below-mentioned segments:

Global Leukemia Therapeutics Market, By Type of Leukemia

• Chronic Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Acute Lymphocytic Leukemia
• Acute Myeloid Leukemia
• Others

Global Leukemia Therapeutics Market, By Treatment

• Chemotherapy
• Immunotherapy
• Targeted Therapy
• CAR-T Cell Therapy
• Others

Global Leukemia Therapeutics Market, By Route of Administration

• Oral
• Injectable

Global Leukemia Therapeutics Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa